CEFYBO   02669
CENTRO DE ESTUDIOS FARMACOLOGICOS Y BOTANICOS
Unidad Ejecutora - UE
congresos y reuniones científicas
Título:
Exosomes displaying high expression of CD24 and HSP90 induced cellular and humoral immune response “in vivo”
Autor/es:
MONGINI CLAUDIA; DE TORO JULIETA; DI SCIULLO PAULA; MENAY FLORECIA; GRAVISACO MARÍA JOSÉ; VENDRELL ALEJANDRINA; WALDNER CLAUDIA; HERSCHLIK LETICIA
Lugar:
Milano
Reunión:
Congreso; 15th International Congress of Immunology (ICI); 2013
Institución organizadora:
International Union of Immunological Societies (IUIS)
Resumen:
Exosomes have emerged as a new approach for the diagnosis and therapy of cancer. The use of these nano-vesicles as modulators of the immune system is being studied presenting them as readily available and stable tumor antigens. The objective of this work was to characterize exosomes derived from the murine T-cell lymphoma LBC and their immunogenic properties. The expression of proteins of immunological relevance, such as MHC I, CD8, CD24 and Hsp90 on exosomes membrane was demonstrated. We demonstrated surface expression of Hsp90 and intralumen Hsp70, indicative of a different protein expression pattern with the cells from which they derive. An over-expression of tumor associated antigens on LBC exosomes when compared to LBC cell lysates or even to intact LBC cells, corresponding to proteins of 51 kDa on LBC-derived exosomes that could not be detected in LBC cells, was found. These tumor antigens were recognized not only by memory lymphocytes but also induced a primary immune response in vitro and a humoral and cellular immune response in vivo, as INF gamma secreted LBC-sensitized splenocytes and specific antibodies were identified in the sera of mice immunized with LBC exosomes. In conclusion, the association of tumor-associated antigens and other molecules of immunologic interest such as MHC, Hsp or costimulatory molecules on tumor exosomes might determine their immune properties. All these findings confirm exosomes as promising defined acellular tumor antigens for the development of an antitumor vaccine for the immunotherapy of cancer.